Mesa Laboratories, Inc.
MLABTechnologyNASDAQScientific & Technical Instruments
Scan Results
Daily timeframeHeadquartered within the technology sector, Mesa Laboratories, Inc. focuses on Scientific & Technical Instruments services and products. Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The company carries a $720.0M market cap, placing it firmly in the small-cap category. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Market Cap
$720.0M
Beta
1.05
P/E (TTM)
151.36
P/E (Fwd)
12.53
EPS (TTM)
$0.85
EPS (Fwd)
$10.27
ROE
2.7%
ROA
3.3%
Cash
$32.2M
Total Debt
$161.4M
Free CF
$53.4M
52W Change
62.5%
Annual Financials
Cash vs Debt
Where MLAB stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, MLAB finished 21.16% above its 150-day moving average ($105.24) and 26.77% above its 200-day moving average ($100.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MLAB overbought or oversold?
At the October 12, 2026 close, MLAB's RSI(14) was 45.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mesa Laboratories, Inc. carries $161.4M in total debt against $32.2M in cash reserves — debt is roughly 5.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $53.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 2.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $219.1M to $249.1M.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. At over 50x earnings, MLAB carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Mesa Laboratories, Inc.'s trajectory.